A stock in the biotechnology and drugs complex that's trading within range of triggering a near-term breakout trade is
(NKTR - Get Report), which is developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms.
If you look at the chart for Nektar Therapeutics, you'll see that this stock made a monster move higher from its June low of $6.40 a share to its July high of $9.94 a share. Following that explosive move higher, shares of NKTR pulled back and entered a sideways trading pattern between $7.86 and $8.73 a share. Traders should now watch NKTR for a high-volume move outside of that sideways trading pattern, since that could trigger a powerful breakout trade.
>>22 Biopharma Stocks With Breakout Potential in 2012
Market players should now look for long-biased trades in NKTR if it can manage to trigger a move above some near-term overhead resistance at $8.73 a share with high volume. Look for a sustained move or close above $8.73 a share with volume that hits near or above its three-month average action of 926,631 shares. If that breakout triggers soon, then NKTR could easily tag or take out its July high of $9.94 a share.
One could look to buy NKTR off weakness and anticipate that breakout, with a stop that sits just below $7.86 a share. Or, one could buy off strength once NKTR clears $8.73 with high volume, and then use a stop just below its 50-day at $8.45 or below $8 a share.
Keep in mind that NKTR is a favorite target of the short-sellers. The current short interest as a percentage of the float for NKTR is very high at 15.5%. If that breakout triggers soon, then we could see a large short squeeze develop, so keep NKTR on your breakout trading radar.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts